BioArctic

BioArctic EBIT Growth

The Year-over-Year EBIT Growth of BioArctic (BIOA B.ST) as of Nov 9, 2026 is 698.71 %. In the previous year, Year-over-Year EBIT Growth was -190.45 % — a change of -466.87% (higher).

EBIT Growth

698.71 %

YoY

-466.87%

Last updated:

Year-over-Year EBIT Growth of BioArctic is 2025 698.71 % . Year-over-Year EBIT Growth of BioArctic was 2024 -190.45 % . It decreases by -466.87% higher compared to the previous year.

The BioArctic EBIT Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Growth
Date
EBIT Growth
Jan 1, 2018
2,344.28 SEK
Jan 1, 2019
-76.64 SEK
Jan 1, 2020
-175.43 SEK
Jan 1, 2021
-63.01 SEK
Jan 1, 2022
92.72 SEK
Jan 1, 2023
2,586.86 SEK
Jan 1, 2024
-190.45 SEK
Jan 1, 2025
698.71 SEK
The BioArctic EBIT Growth history
YEAREBIT GrowthYoY
698.71 %-466.87%
-190.45 %-107.36%
2,586.86 %+2,690.00%
92.72 %-247.14%
-63.01 %-64.08%
-175.43 %+128.89%
-76.64 %-103.27%
2,344.28 %-3,295.26%
-73.37 %-105.09%
1,440.69 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioArctic Stock analysis

What does BioArctic do? BioArctic AB is a Swedish biotechnology company founded in 2003. The company is based in Stockholm and focuses on the development of innovative therapeutics for nervous system diseases such as Alzheimer's, Parkinson's, and spinal cord injuries. The company uses its expertise in biological and chemical drug research to discover and develop new therapeutic possibilities, with a focus on Amyloid-Beta production. BioArctic's business strategy is based on partnerships with pharmaceutical and biotech companies worldwide, working closely with partners to develop therapies and products that meet the needs and expectations of patients and doctors. BioArctic conducts research in three different areas: Alzheimer's, Parkinson's, and spinal cord injuries. The company works with partners such as Nutricia, Eisai, Just Biotherapeutics, Abcam, Neuropharm, AbbVie, Q-Med, Uppsala University, and the Karolinska Institute to develop treatments for these conditions. BioArctic has already brought several promising products to market, including BAN2401 for Alzheimer's and SC0806 for spinal cord injuries. Overall, BioArctic is a leading company in biological and chemical drug research, with a focus on developing new therapies and products for the benefit of patients and doctors worldwide. BioArctic is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioArctic stock

Year-over-Year EBIT Growth of BioArctic is 698.71 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year EBIT Growth BioArctic since 2006 – with annual values, charts, and detailed analysis.

EBIT growth measures the percentage change in operating earnings. It shows whether a company's core operations are becoming more profitable.

To evaluate Year-over-Year EBIT Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year EBIT Growth.

Year-over-Year EBIT Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year EBIT Growth's BioArctic historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — BioArctic

All Key Metrics — BioArctic